Text Size

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
Sir Charles Gairdner Hospital
ClinicalTrials.gov Identifier:
NCT00382044
First received: September 27, 2006
Last updated: May 22, 2008
Last verified: May 2008
History of Changes
  Purpose

The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.


Condition Intervention
Kidney Failure, Chronic
Anemia
 Drug: Eprex; Neorecormon; Aranesp

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sir Charles Gairdner Hospital:

Estimated Enrollment: 150
Study Start Date: September 2006
Study Completion Date: April 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • On haemodialysis at a Sir Charles Gairdner Hospital Unit
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00382044

Locations
Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Sponsors and Collaborators
Sir Charles Gairdner Hospital
Investigators
Study Director: Neil C Boudville, MBBS Sir Charles Gairdner Hospital
  More Information

No publications provided

Responsible Party: Dr Neil Boudville, Sir Charles Gairdner Hospital
ClinicalTrials.gov Identifier: NCT00382044     History of Changes
Other Study ID Numbers: NB-06-10
Study First Received: September 27, 2006
Last Updated: May 22, 2008
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Sir Charles Gairdner Hospital:
Kidney Failure, Chronic
Dialysis
Anemia
epoetin

Additional relevant MeSH terms:
Anemia
Kidney Failure, Chronic
Renal Insufficiency
Hematologic Diseases
Renal Insufficiency, Chronic
Kidney Diseases
 Urologic Diseases
Darbepoetin alfa
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013